Vertex Pharmaceuticals’ (VRTX) “Outperform” Rating Reaffirmed at William Blair
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...
Vertex Therapeutics: The Pain Comes With The Territory For Suzetrigine
I last wrote here several months ago about the sodium channel (NaV1.8) inhibitor VX-548 (now known as suzetrigine), which is ...
manilatimes1d
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones
Continue advancing our pipeline candidates, with several key updates in 2025, including CTX112™ in oncology and autoimmune ...
TD Cowen Keeps Their Buy Rating on Rhythm Pharmaceuticals (RYTM)
TD Cowen analyst Phil Nadeau maintained a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report) today. The company’s shares opened ...
Le Lézard4d
A Blockbuster Year for Concierge Medicine: Specialdocs Reports a Record 26 Physician-Clients Launched Practices in 2024
Concierge medicine experts Specialdocs Consultants broadened its footprint considerably in 2024, welcoming a record 26 new physician clients to its rapidly growing national network of outstanding ...
Stifel Nicolaus Remains a Buy on Rapport Therapeutics, Inc. (RAPP)
Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Rapport Therapeutics, Inc. (RAPP – Research Report) yesterday. The company’s ...
The Massachusetts biotech industry rebounded in 2024. Can the momentum last?
The industry continues to face financial and regulatory headwinds, including high interest rates and uncertainty about ...
Barchart on MSN5d
Vertex Pharmaceuticals Earnings Preview: What to Expect
Vertex Pharmaceuticals Incorporated (VRTX), headquartered in Boston, Massachusetts, is a global leader in biotechnology and ...
CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRSP), a biopharmaceutical company focused on ...